Advances in Cellular and Humoral Immunotherapy - Implications for the Treatment of Poor Risk Childhood, Adolescent, and Young Adult B-Cell Non-Hodgkin Lymphoma
Patients with relapsed, refractory or advanced stage B non-Hodgkin lymphoma (NHL) continue to have a dismal prognosis. This review summarises current and novel cellular and immunotherapy for these high-risk populations, including haematopoietic stem cell transplant, bispecific antibodies, viral-derived cytotoxic T cells, chimeric antigen receptor (CAR) T cells, and natural killer (NK) cell therapy, as discussed at the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma on September 26th-29th 2018 in Rotterdam, the Netherlands, and explores the future of NK/CAR NK therapies.
Chu, Y., Gardenswartz, A., Termuhlen, A., & Cairo, M. (2019). Advances in Cellular and Humoral Immunotherapy - Implications for the Treatment of Poor Risk Childhood, Adolescent, and Young Adult B-Cell Non-Hodgkin Lymphoma. British Journal of Haematology, 185 (6), 1055-1070. https://doi.org/10.1111/bjh.15753